Rocket Lab USA Inc. officer Arjun Kampani filed Form 144 on 3/4/2026, notifying of a proposed sale of 23,711 shares of common stock under Rule 144. These shares were acquired on 3/1/2026 through the vesting of restricted stock units directly from the issuer, with no payment required beyond standard vesting terms. The aggregate market value is $1,662,852.43 based on NASDAQ pricing, against 567,445,449 shares outstanding. Kampani recently sold 28,761 shares on 3/1/2026 for gross proceeds of $2,001,475.11. The transaction relies on a pre-established Rule 10b5-1 trading plan adopted on 9/19/2025, which allows insiders to schedule sales to avoid insider trading concerns. Broker is Morgan Stanley Smith Barney LLC. Kampani represents no undisclosed material adverse information. This filing aligns with Rocket Lab's compensation practices for executives, where RSU vesting often triggers sales to cover tax obligations or diversify holdings.

This routine RSU vesting sale by officer Arjun Kampani represents minimal dilution (~0.004% of shares outstanding) and is pre-planned under Rule 10b5-1, signaling no new concerns about company prospects as Kampani affirms no undisclosed adverse info. Near-term stock impact is negligible given the small size relative to market cap, but investors should monitor cumulative insider sales around vesting dates for sentiment. Strategically, it reflects standard executive compensation liquidity without altering Rocket Lab's operational trajectory; watch future 10b5-1 plan disclosures or Form 4s for patterns.